These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 108704)

  • 81. Discriminative stimulus properties of quipazine: direct serotonergic mediation.
    White FJ; Appel JB; Kuhn DM
    Neuropharmacology; 1979 Feb; 18(2):143-51. PubMed ID: 34803
    [No Abstract]   [Full Text] [Related]  

  • 82. [Pharmacological properties of indolylalkyl derivatives of quipazine].
    Trubitsyna TK; Kashkovskiĭ MD
    Farmakol Toksikol; 1980; 43(5):530-6. PubMed ID: 7449980
    [TBL] [Abstract][Full Text] [Related]  

  • 83. LSD, 5-HT (serotonin), and the evolution of a behavioral assay.
    Appel JB; West WB; Buggy J
    Neurosci Biobehav Rev; 2004 Jan; 27(8):693-701. PubMed ID: 15019419
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The effects of quipazine on 5-HT metabolism in the rat brain.
    Hamon M; Bourgoin S; Enjalbert A; Bockaert J; Hery F; Ternaux JP; Glowinski J
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Jul; 294(1):99-108. PubMed ID: 1004632
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.
    Berg KA; Maayani S; Goldfarb J; Scaramellini C; Leff P; Clarke WP
    Mol Pharmacol; 1998 Jul; 54(1):94-104. PubMed ID: 9658194
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Evidence for the action of d-lysergic acid diethylamide, mescaline and bufotenine on 5-hydroxytryptamine receptors in umbilical vasculature.
    Dyer DC
    J Pharmacol Exp Ther; 1974 Feb; 188(2):336-41. PubMed ID: 4359552
    [No Abstract]   [Full Text] [Related]  

  • 87. Quipazine exacerbation of a hyperkinetic syndrome: involvement of brain dopamine and serotonin.
    Langlais PJ; Gabay S
    J Neurosci Res; 1977; 3(2):135-41. PubMed ID: 563925
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Patterns of tolerance to lysergic acid diethylamide and mescaline in rats.
    FREEDMAN DX; AGHAJANIAN GK; ORNITZ EM
    Science; 1958 May; 127(3307):1173-4. PubMed ID: 13555858
    [No Abstract]   [Full Text] [Related]  

  • 89. Quipazine has a biphasic effect on slow wave sleep and reduces REM sleep rebound in REM sleep deprived rats.
    Zak R; Radulovacki M
    Brain Res Bull; 1982 Mar; 8(3):329-31. PubMed ID: 7093740
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Serotonin type 2 antagonists inhibit lordosis behavior in the female rat: reversal with quipazine.
    Mendelson SD; Gorzalka BB
    Life Sci; 1986 Jan; 38(1):33-9. PubMed ID: 2934598
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Serotonin and behavioral inhibition.
    Stein L; Wise CD
    Adv Biochem Psychopharmacol; 1974; 11(0):281-91. PubMed ID: 4276861
    [No Abstract]   [Full Text] [Related]  

  • 92. Lisuride and LSD: dopaminergic and serotonergic interactions in the "serotonin syndrome".
    Silbergeld EK; Hruska RE
    Psychopharmacology (Berl); 1979 Nov; 65(3):233-7. PubMed ID: 117494
    [No Abstract]   [Full Text] [Related]  

  • 93. A neuropharmacological analysis of the discriminative stimulus properties of fenfluramine.
    White FJ; Appel JB
    Psychopharmacology (Berl); 1981; 73(2):110-5. PubMed ID: 6785800
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Influence of mescaline and of lysergic acid diethylamide (LSD-25) on the development of primary and secondary conditioned avoidance reflexes in rats].
    MAFFII G
    Farmaco Sci; 1959 Jul; 14():503-15. PubMed ID: 13853753
    [No Abstract]   [Full Text] [Related]  

  • 95. The influence of quipazine on the turnover rate of serotonin.
    Grabowska M; Antkiewicz L; Michaluk J
    Biochem Pharmacol; 1974 Nov; 23(22):3211-2. PubMed ID: 4441411
    [No Abstract]   [Full Text] [Related]  

  • 96. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor.
    Smith RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1995 Nov; 275(2):1050-7. PubMed ID: 7473132
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Is Ro 11-2465 (cyan-imipramine) an antagonist of postsynaptic serotonin receptors?
    Pawłowski L; Kwiatek H; Górka Z
    J Neural Transm; 1981; 52(1-2):61-72. PubMed ID: 7288439
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Interactions of metergoline with diazepam, quipazine, and hallucinogenic drugs on a conflict behavior in the rat.
    Commissaris RL; Rech RH
    Psychopharmacology (Berl); 1982; 76(3):282-5. PubMed ID: 6808551
    [No Abstract]   [Full Text] [Related]  

  • 99. Comparison of the effects of d-amphetamine and lysergic acid diethylamide in two strains of rats having different behavioral baselines.
    Tilson HA; Maisel AS; Jourdan MG; Rech RH
    Behav Biol; 1976 Aug; 17(4):463-71. PubMed ID: 971196
    [No Abstract]   [Full Text] [Related]  

  • 100. Acrylamide neurotoxicity: altered spinal monosynaptic responses to quipazine, a serotonin agonist, in cats.
    Goldstein BD
    Toxicol Appl Pharmacol; 1985 May; 78(3):436-44. PubMed ID: 2996174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.